Madera Therapeutics focuses on innovative cancer treatment strategies by targeting mitochondrial function, specifically through the activation of mitochondrial proteases. Their lead technology involves the selective activation of ClpP, a mitochondrial protease, which alters the metabolism of cancer cells. This approach aims to disrupt the unique energy requirements of tumors, particularly in drug-resistant cancer types. Madera's compounds have demonstrated efficacy in both in vitro and in vivo studies, showcasing their potential to treat challenging cancers by leveraging a novel mechanism of action. The company boasts a robust patent portfolio that supports its research and development efforts in this area.

In addition to their proprietary technologies, Madera Therapeutics collaborates with a network of academic institutions and research organizations to enhance their drug discovery processes. The management team, which includes experts with extensive backgrounds in drug development and oncology, employs an open innovation model to drive research forward. Collaborators are actively engaged in studying and validating Madera's compounds, contributing to a comprehensive understanding of their therapeutic potential. This collaborative approach, combined with a strong focus on mitochondrial biology, positions Madera Therapeutics as a leader in the development of next-generation cancer therapeutics.

United States

Madera is the leader in highly potent and specific activators of the mitochondrial protease, ClpP. Together with our academic collaborators and the NIH/NCI, we have established the in vitro and in vivo performance of these agents. Notably, our agents provide a new mechanism of action that is effective on a number of drug-resistant cancer cells and patient-derived tissue samples. This technology is backed by the broadest patent portfolio in the area.

Madera Therapeutics

Company Details